胃肠道间质瘤临床病理诊断分析
Clinicopathological Diagnosis and Analysis of Gastrointestinal Stromal Tumors
DOI: 10.12677/ACM.2024.141198, PDF,   
作者: 蒙 杰*, 许新才#：新疆医科大学第一附属医院胃肠外科，新疆 乌鲁木齐
关键词: 胃肠道间质瘤；临床病理特征；免疫组化；诊断；综述；Gastrointestinal Stromal Tumor； Clinicopathological Features； Immunohistochemistry； Diagnosis； Summary
摘要: 胃肠道间质瘤(GIST)发病率不断上升，其临床表现为非特异性呈多元化，无症状患者在内镜检查或影像学检查中偶然发现。大多数GIST为良性肿瘤，其中20%~30%为恶性肿瘤。病理诊断标准包括组织形态学(梭形细胞型，上皮样细胞型，混合型)，并辅以免疫组化标记物(主要是CD117、DOG-1)。治疗的金标准是手术切除，伊马替尼是一种酪氨酸激酶抑制剂，是治疗手术难以切除、复发性和转移性GIST的首选方案。本文对目前GIST的临床病理、形态特征和诊断方法进行综述。
Abstract: The incidence of gastrointestinal stromal tumor (GIST) is increasing, and its clinical manifestations are non-specific and diversified. Asymptomatic patients are occasionally found in endoscopy or im-aging examination. Most GIST are benign tumors, of which 20%~30% are malignant tumors. The pathological diagnostic criteria included histomorphology (spindle cell type, epithelioid cell type, mixed type) and immunohistochemical markers (mainly CD117, DOG-1). The gold standard of treatment is surgical resection. Imatinib, a tyrosine kinase inhibitor, is the first choice for the treatment of unresectable, recurrent and metastatic GIST. This article reviews the clinicopathology, morphological features and diagnostic methods of GIST.
文章引用：蒙杰, 许新才. 胃肠道间质瘤临床病理诊断分析[J]. 临床医学进展, 2024, 14(1): 1375-1382. https://doi.org/10.12677/ACM.2024.141198

参考文献

[1] Nishida, T., Yoshinaga, S., Takahashi, T. and Naito, Y. (2021) Recent Progress and Challenges in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors. Cancers, 13, Article 3158. [Google Scholar] [CrossRef] [PubMed]
[2] Mantese, G. (2019) Gastrointestinal Stromal Tumor: Epidemiology, Diagnosis, and Treatment. Current Opinion in Gastroenterology, 35, 555-559. [Google Scholar] [CrossRef] 
[3] Hirota, S., Isozaki, K., Moriyama, Y., et al. (1998) Gain-of-Function Mutations of c-Kit in Human Gastrointestinal Stromal Tumors. Science, 279, 577-580. [Google Scholar] [CrossRef] [PubMed]
[4] Heinrich, M.C., Corless, C.L., Duensing, A., et al. (2003) PDGFRA activating Mutations in Gastrointestinal Stromal Tumors. Science, 299, 708-710. [Google Scholar] [CrossRef] [PubMed]
[5] Agaram, N.P., Wong, G.C., Guo, T., et al. (2008) Novel V600E BRAF Mutations in Imatinib-Naive and Imatinib-Resistant Gastrointestinal Stromal Tumors. Genes, Chromosomes & Cancer, 47, 853-859. [Google Scholar] [CrossRef] [PubMed]
[6] Agaimy, A., Terracciano, L.M., Dirnhofer, S., et al. (2009) V600E BRAF Mutations Are Alternative Early Molecular Events in a Subset of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumours. Journal of Clinical Pathology, 62, 613-616. [Google Scholar] [CrossRef] [PubMed]
[7] Lasota, J., Fe-lisiak-Golabek, A., Wasag, B., et al. (2016) Frequency and Clinicopathologic Profile of PIK3CA Mutant GISTs: Molec-ular Genetic Study of 529 Cases. Modern Pathology, 29, 275-282. [Google Scholar] [CrossRef] [PubMed]
[8] Shi, S.S., Wu, N., He, Y., et al. (2017) EGFR Gene Mutation in Gastrointestinal Stromal Tumours. Histopathology, 71, 553-561. [Google Scholar] [CrossRef] [PubMed]
[9] Brenca, M., Rossi, S., Polano, M., et al. (2016) Transcriptome Sequencing Identifies ETV6-NTRK3 as a Gene Fusion Involved in GIST. The Journal of Pathology, 238, 543-549. [Google Scholar] [CrossRef] [PubMed]
[10] Shi, E., Chmielecki, J., Tang, C.M., et al. (2016) FGFR1 and NTRK3 Actionable Alterations in “Wild-Type” Gastrointestinal Stromal Tumors. Journal of Translational Medicine, 14, Article No. 339. [Google Scholar] [CrossRef] [PubMed]
[11] Boikos, S.A., Pappo, A.S., Killian, J.K., et al. (2016) Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncology, 2, 922-928. [Google Scholar] [CrossRef] [PubMed]
[12] Ma, G.L., Murphy, J.D., Martinez, M.E., et al. (2015) Epidemi-ology of Gastrointestinal Stromal Tumors in the Era of Histology Codes: Results of a Population-Based Study. Cancer Epidemiology, Biomarkers & Prevention, 24, 298-302. [Google Scholar] [CrossRef] 
[13] Von Mehren, M. and Joensuu, H. (2018) Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 36, 136-143. [Google Scholar] [CrossRef] 
[14] Janeway, K.A., Kim, S.Y., Lodish, M., et al. (2011) Defects in Succinate Dehydrogenase in Gastrointestinal Stromal Tumors Lacking KIT and PDGFRA Mutations. Proceedings of the National Academy of Sciences of the United States of America, 108, 314-318. [Google Scholar] [CrossRef] [PubMed]
[15] Ranchod, M. and Kempson, R.L. (1977) Smooth Muscle Tumors of the Gastrointestinal Tract and Retroperitoneum: A Pathologic Analysis of 100 Cases. Cancer, 39, 255-262. [Google Scholar] [CrossRef] 
[16] Miettinen, M. (1988) Gastrointestinal Stromal Tumors. An Immunohistochemical Study of Cellular Differentiation. American Journal of Clinical Pathology, 89, 601-610. [Google Scholar] [CrossRef] [PubMed]
[17] Mazur, M.T. and Clark, H.B. (1983) Gastric Stromal Tumors Reappraisal of Histogenesis. The American Journal of Surgical Pathology, 7, 507-520. [Google Scholar] [CrossRef] [PubMed]
[18] Dematteo, R.P., Lewis, J.J., Leung, D., et al. (2000) Two Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival. Annals of Sur-gery, 231, 51. [Google Scholar] [CrossRef] [PubMed]
[19] Wu, J., Zhou, H., Yi, X., et al. (2021) Targeted Deep Sequencing Reveals Unrecognized KIT Mutation Coexistent with NF1 Deficiency in GISTs. Cancer Management and Research, 13, 297-306. [Google Scholar] [CrossRef] 
[20] Brcic, I., Kashofer, K., Skone, D. and Liegl-Atzwanger, B. (2019) KIT Mutation in a Naïve Succinate Dehydrogenase-Deficient Gastric GIST. Genes, Chro-mosomes & Cancer, 58, 798-803. [Google Scholar] [CrossRef] [PubMed]
[21] Nishida, T., Doi, T. and Naito, Y. (2014) Tyrosine Kinase Inhibitors in the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors. Expert Opin-ion on Pharmacotherapy, 15, 1979-1989. [Google Scholar] [CrossRef] [PubMed]
[22] Rubin, B.P., Heinrich, M.C. and Corless, C.L. (2007) Gas-trointestinal Stromal Tumour. The Lancet, 369, 1731-1741. [Google Scholar] [CrossRef] 
[23] Heinrich, M.C., Griffith, D.J., Druker, B.J., et al. (2000) In-hibition of c-Kit Receptor Tyrosine Kinase Activity by STI 571, a Selective Tyrosine Kinase Inhibitor. Blood, 96, 925-932. [Google Scholar] [CrossRef] 
[24] Demetri, G.D., Von Mehren, M., Blanke, C.D., et al. (2002) Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. The New England Journal of Medicine, 347, 472-480. [Google Scholar] [CrossRef] 
[25] Kelly, C.M., Gutierrez Sainz, L. and Chi, P. (2021) The Management of Metastatic GIST: Current Standard and Investigational Therapeutics. Journal of Hematology & Oncology, 14, Article No. 2. [Google Scholar] [CrossRef] [PubMed]
[26] Verweij, J., Casali, P.G., Zalcberg, J., et al. (2004) Progres-sion-Free Survival in Gastrointestinal Stromal Tumours with High-Dose Imatinib: Randomised Trial. The Lancet, 364, 1127-1134. [Google Scholar] [CrossRef] 
[27] Blanke, C.D., Rankin, C., Demetri, G.D., et al. (2008) Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate at Two Dose Levels in Patients with Unre-sectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. Journal of Clinical Oncology, 26, 626-632. [Google Scholar] [CrossRef] 
[28] Von Mehren, M., Randall, R.L., Benjamin, R.S., et al. (2014) Gastrointestinal Stromal Tumors, Version 2.2014. Journal of the National Comprehensive Cancer Network, 12, 853-862. [Google Scholar] [CrossRef] [PubMed]
[29] Casali, P.G., Abecassis, N., Aro, H.T., et al. (2018) Gastrointestinal Stromal Tumours: ESMO-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 29, iv267.
[30] Smith, B.D., Kaufman, M.D., Lu, W.P., et al. (2019) Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell, 35, 7387-51.E9. [Google Scholar] [CrossRef] [PubMed]
[31] Evans, E.K., Gardino, A.K., Kim, J.L., et al. (2017) A Precision Therapy against Cancers Driven by KIT/PDGFRA Mutations. Science Translational Medicine, 9, eaao1690. [Google Scholar] [CrossRef] [PubMed]
[32] Tan, Y., Tan, L., Lu, J., et al. (2017) Endoscopic Resection of Gastric Gastrointestinal Stromal Tumors. Translational Gastroenterology and Hepatology, 2, Article 115. [Google Scholar] [CrossRef] [PubMed]
[33] Madhusudhan, K.S. and Das, P. (2022) Mesenchymal Tumors of the Stomach: Radiologic and Pathologic Correlation. Abdominal Radiology, 47, 1988-2003. [Google Scholar] [CrossRef] [PubMed]
[34] Blay, J.Y., Kang, Y.K., Nishida, T. and von Mehren, M. (2021) Gastrointestinal Stromal Tumours. Nature Reviews Disease Primers, 7, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
[35] Nishida, T., Blay, J.Y., Hirota, S., et al. (2016) The Standard Diagnosis, Treatment, and Follow-Up of Gastrointestinal Stromal Tumors Based on Guidelines. Gastric Cancer, 19, 3-14. [Google Scholar] [CrossRef] [PubMed]
[36] Zalupski, M., Metch, B., Balcerzak, S., et al. (1991) Phase III Comparison of Doxorubicin and Dacarbazine Given by Bolus versus Infusion in Patients with Soft-Tissue Sarcomas: A Southwest Oncology Group Study. Journal of the National Cancer Institute, 83, 926-932. [Google Scholar] [CrossRef] [PubMed]
[37] Ryan, D.P., Puchalski, T., Supko, J.G., et al. (2002) A Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients with Gastrointestinal Stromal Tumors. The Oncologist, 7, 531-538. [Google Scholar] [CrossRef] [PubMed]
[38] Trent, J.C., Beach, J., Burgess, M.A., et al. (2003) A Two-Arm Phase II Study of Temozolomide in Patients with Advanced Gastrointestinal Stromal Tumors and Other Soft Tissue Sarcomas. Cancer, 98, 2693-2699. [Google Scholar] [CrossRef] [PubMed]
[39] Lamba, G., Ambrale, S., Lee, B., et al. (2012) Recent Advances and Novel Agents for Gastrointestinal Stromal Tumor (GIST). Journal of Hematology & Oncology, 5, Article No. 21. [Google Scholar] [CrossRef] [PubMed]
[40] 年中国胃肠道间质瘤病理共识意见专家组. 中国胃肠道间质瘤诊断治疗专家共识(2017年版)病理解读[J]. 中华病理学杂志, 2018, 47(1): 2-6.
[41] Miettinen, M., Wang, Z.F. and Lasota, J. (2009) DOG1 Antibody in the Differential Diagnosis of Gastrointestinal Stromal Tumors: A Study of 1840 Cases. The American Journal of Surgical Pathology, 33, 1401-1408. [Google Scholar] [CrossRef] 
[42] Davey, M.G., Hynes, S.O., Kerin, M.J., et al. (2021) Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. Cancers, 13, Article 4455. [Google Scholar] [CrossRef] [PubMed]
[43] Luchini, C., Pantanowitz, L., Adsay, V., et al. (2022) Ki-67 As-sessment of Pancreatic Neuroendocrine Neoplasms: Systematic Review and Meta-Analysis of Manual vs. Digital Pa-thology Scoring. Modern Pathology, 35, 712-720. [Google Scholar] [CrossRef] [PubMed]
[44] Wang, J.P., Liu, L., Li, Z.A., et al. (2021) Ki-67 Labelling Index Is Related to the Risk Classification and Prognosis of Gastrointestinal Stromal Tumours: A Retrospective Study. Gas-troenterologia y Hepatologia, 44, 103-114. [Google Scholar] [CrossRef] [PubMed]
[45] Fletcher, C.D., Berman, J.J., Corless, C., et al. (2002) Diag-nosis of Gastrointestinal Stromal Tumors: A Consensus Approach. International Journal of Surgical Pathology, 10, 81-89. [Google Scholar] [CrossRef] [PubMed]
[46] Miettinen, M. and Lasota, J. (2005) KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation. Ap-plied Immunohistochemistry & Molecular Morphology, 13, 205-220. [Google Scholar] [CrossRef] [PubMed]
[47] Hirota, S. (2018) Differential Diagnosis of Gastrointes-tinal Stromal Tumor by Histopathology and Immunohistochemistry. Translational Gastroenterology and Hepatology, 3, Article 27. [Google Scholar] [CrossRef] [PubMed]
[48] Casali, P.G. and Blay, J.Y. (2010) Gastrointestinal Stro-mal Tumours: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 21, V98-V102. [Google Scholar] [CrossRef] [PubMed]
[49] Beham, A.W., Schaefer, I.M., Schüler, P., et al. (2012) Gastrointestinal Stromal Tumors. International Journal of Colorectal Disease, 27, 689-700. [Google Scholar] [CrossRef] [PubMed]

为你推荐